FDA Clears First OTC Continuous Glucose Monitor for Kids as Young as Two
The FDA cleared Dexcom's Stelo CGM for children 2+, offering real-time glucose tracking without a prescription for young users.
Summary
The FDA has cleared the first over-the-counter continuous glucose monitor for children as young as two years old. Dexcom's Stelo Glucose Biosensor System, already approved for adults since 2024, can now be used without a prescription by children who don't use insulin. The wearable sensor pairs with a smartphone app to display glucose readings every 15 minutes for up to 15 days. With prediabetes rising in children, this tool lets kids and caregivers track how food, exercise, and lifestyle choices affect blood sugar in real time. It's designed for those managing diabetes with oral medications or anyone wanting better glycemic awareness, though it's not suitable for insulin users or those prone to dangerous low blood sugar episodes.
Detailed Summary
Continuous glucose monitoring just became accessible to millions of children without a doctor's prescription. The FDA cleared Dexcom's Stelo Glucose Biosensor System for children aged two and older who do not use insulin, marking the first over-the-counter CGM approved for pediatric use in the United States. This builds on the device's earlier adult clearance from March 2024 and reflects growing regulatory momentum around home-based health monitoring tools.
The timing is significant. Prediabetes rates among children are climbing, putting a growing number of young people on a trajectory toward Type 2 diabetes. Early glycemic awareness, supported by real-time data, offers a meaningful opportunity for behavioral intervention before metabolic dysfunction becomes entrenched. For health-conscious families, this is a practical tool to identify how specific meals, physical activity, sleep, and stress affect glucose patterns in children.
The Stelo system uses a wearable skin sensor paired with a smartphone app to record and display glucose readings every 15 minutes. Each sensor lasts up to 15 days, though wear time may be shorter in children due to physiological differences. The FDA used a combination of prior clinical study data and real-world evidence from existing iCGM users to support the pediatric clearance, a notable regulatory approach that may accelerate future device approvals.
For longevity-oriented readers, the broader implication is that continuous metabolic monitoring is moving into everyday life at earlier ages, enabling proactive rather than reactive health management. Tracking glucose variability is increasingly recognized as a key biomarker for metabolic health, inflammation risk, and long-term cardiovascular outcomes.
Important caveats apply. The device does not alert users to dangerous low blood sugar episodes, making it unsuitable for those with hypoglycemia concerns. It is also not approved for people on dialysis, and those with eating disorder histories should consult a physician before use. Any medication adjustments based on readings require healthcare provider guidance.
Key Findings
- FDA cleared Dexcom Stelo CGM for children aged 2+ without a prescription, a pediatric first.
- Device displays real-time glucose readings every 15 minutes via smartphone app for up to 15 days.
- Prediabetes is rising in children, making early glucose monitoring a critical prevention tool.
- Approval used real-world evidence alongside clinical data, signaling a faster regulatory pathway for devices.
- Not suitable for insulin users, dialysis patients, or those with hypoglycemia vulnerability.
Methodology
This is an official FDA press release, representing the highest regulatory authority on medical device clearance. Evidence basis includes prior clinical trial data from pediatric and adult populations combined with real-world evidence from existing iCGM users. No independent peer-reviewed study is cited directly, so clinical performance details should be verified against Dexcom's published data.
Study Limitations
This is a regulatory clearance announcement, not a clinical outcomes study, so long-term efficacy data in children is not provided. Sensor wear duration may be shorter in children than adults, and individual variability in performance is not quantified. Independent clinical validation of pediatric-specific glucose accuracy should be reviewed before clinical recommendations are made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.